Prime Medicine Inc. (PRME): Price and Financial Metrics Recent IPO
GET POWR RATINGS... FREE!
PRME Stock Price Chart Interactive Chart >
PRME Price/Volume Stats
| Current price | $12.30 | 52-week high | $21.73 |
| Prev. close | $12.28 | 52-week low | $11.07 |
| Day low | $11.88 | Volume | 196,530 |
| Day high | $12.43 | Avg. volume | 167,099 |
| 50-day MA | $16.20 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 1.20B |
Latest PRME News From Around the Web
Below are the latest news stories about PRIME MEDICINE INC that investors may wish to consider to help them evaluate PRME as an investment opportunity.
Prime Medicine to Present at Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease DaysCAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days on Monday, April 3, 2023 at 3:55 p.m. ET in New York, NY. A live audio webcast o |
Prime Medicine Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update-- Announced preclinical data providing further proof-of-concept for Prime Editing’s ability to achieve restoration of genetic function, as well as new preliminary safety analyses demonstrating no detected off-target activity -- -- Nominated PM359, first development candidate for the treatment of Chronic Granulomatous Disease (CGD) -- -- Successfully completed upsized initial public offering, raising $199 million in gross proceeds -- CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Prime Med |
Prime Medicine to Present at Cowen 43rd Annual Health Care ConferenceCAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 9:50 a.m. ET in Boston, MA. A live audio webcast of the presentation will be avail |
We Think Prime Medicine (NASDAQ:PRME) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Prime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities-- New preclinical data in Friedrich’s ataxia and cystic fibrosis provided further proof-of-concept for Prime Editing’s ability to achieve restoration of genetic function ---- New preliminary safety analyses demonstrated no detected off-target activity in Prime Edited Wilson’s disease cells ---- New data leveraging PASSIGE technology demonstrated ability to integrate kilobase-sized DNA in human T cells ---- Additional LNP and AAV delivery data demonstrated efficient in vivo delivery of Prime Edi |
PRME Price Returns
| 1-mo | -24.72% |
| 3-mo | -33.80% |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -33.80% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...